Waters Corporation (WAT) Sinks 10.04% After Earnings, EPS Exceeds Estimates and Beats Revenue

2026-02-09 · Stocks · QuoteReporter

Post Earning Analysis

Waters Corporation (WAT) Sinks 10.04% After Earnings, EPS Exceeds Estimates and Beats Revenue

Waters Corp., founded by James Logan Waters in 1958 and headquartered in Milford, MA, specializes in providing advanced workflow solutions through its expertise in liquid chromatography, mass spectrometry, and thermal analysis. The company operates through two segments: Waters, focused on chromatography and mass spectrometry technologies, and TA Instruments, which offers thermal analysis, rheometry, and calorimetry solutions.

Waters Corporation (NYSE: WAT) recently completed a significant business combination with Becton Dickinson’s (BD) Biosciences and Diagnostic Solutions businesses. This strategic move, reported on February 9, 2026, aims to enhance Waters’ capabilities in the biosciences and diagnostic sectors. On the same day, Waters also announced their fourth-quarter earnings, surpassing both earnings and revenue estimates, which could reflect positively on the stock as it demonstrates the company’s robust financial health and operational efficiency.

However, Becton Dickinson, following the spinoff, has slashed its profit outlook, which could indicate potential challenges or costs associated with the restructuring process that might impact Waters indirectly, especially considering the integration processes typically associated with such large-scale combinations. The full impact of these developments on Waters’ stock will depend on the company’s ability to effectively integrate the new business units and realize synergies that contribute to long-term growth and profitability.

The current price of $340.78 represents a significant drop of 10.04% today, positioning it closer to the week’s low of $328.06 than the high of $344.97. This sharp decline is reflected in the negative percentage differences from both the 20-day (-11.37%) and 50-day (-12.13%) moving averages, suggesting a bearish trend in the short term. However, the price remains relatively stable compared to the 200-day moving average, with only a -1.16% difference.

The stock is currently trading 17.91% below its 52-week high of $415.11 and has recovered 23.9% from its 52-week and year-to-date lows of $275.05, indicating some resilience over the longer term. The Relative Strength Index (RSI) at 27.83 signals that the stock might be oversold, which could potentially attract buying interest if investors perceive it as undervalued. However, the Moving Average Convergence Divergence (MACD) at -5.7 supports the view of ongoing bearish momentum. This combination of factors suggests caution, as the stock shows both potential for a rebound and risk of further declines.

Waters Corporation (WAT) reported a robust financial performance in Q4 2025, with sales increasing by 7% year-over-year to $932 million, driven by significant growth in the pharmaceutical and industrial markets. The company’s pharmaceutical market sales rose by 8%, while industrial market sales also saw an 8% increase. However, academic and government market sales slightly declined by 2%. Chemistry product sales, particularly in bioseparations, surged by 12% in constant currency, and instruments sales grew by 3%, buoyed by strong demand in LC-MS systems.

For the full year 2025, Waters Corporation’s total sales were $3,165 million, marking a 7% increase from 2024. The pharmaceutical sector continued to be a strong contributor, with a 9% rise in sales, and industrial sales grew by 6%. Recurring revenues for the year increased by 8% in constant currency.

The company reported a GAAP EPS of $3.77 for the quarter, slightly down from $3.88 in Q4 2024, and a non-GAAP EPS of $4.53, up 10% year-over-year. For the entire year, GAAP EPS was $10.76, and non-GAAP EPS improved by 11% to $13.13.

Geographically, sales in Asia and Europe showed robust growth, with Asia reporting a full-year increase of 13% in constant currency and Europe 5%. The Americas region also posted steady growth.

Looking ahead to 2026, Waters Corporation expects organic constant currency revenue growth between 5.5% and 7.0%, with total revenue projected to be between $6.405 billion and $6.455 billion. The company anticipates a non-GAAP EPS range of $14.30 to $14.50, representing an 8.9% to 10.4% increase from 2025.

Earnings Trend Table

The provided earnings data reveals a consistent trend of companies surpassing their estimated earnings per share (EPS) across multiple quarters. Notably, every reported EPS from Q4 2023 to Q3 2025 exceeded the estimates, suggesting a pattern of conservative forecasting or operational performance exceeding expectations.

A closer analysis shows that the largest surprises in EPS occurred in Q4 of both 2023 and 2024, with surprise percentages of 11.39% and 9.37% respectively. This could indicate a trend where the final quarter of the year tends to yield better-than-expected financial results, possibly due to end-of-year sales boosts or cost efficiencies realized throughout the year.

The quarters in 2025 display a continuation of this trend but with varying degrees of surprise. The highest was in Q3 2025 with a 5.92% surprise, followed by more modest outperformances earlier in the year. The consistency in exceeding EPS estimates not only highlights effective management strategies but also suggests a potential underestimation of the company’s earnings potential by analysts.

Overall, the persistent positive surprises in EPS across these quarters could be a strong signal to investors regarding the robustness of the company’s financial health and operational efficiency.

The recent analyst ratings for the company under review have shown a generally positive outlook from various financial institutions, indicating potential growth or a robust position in its sector.

1. Guggenheim (January 6, 2026): This firm initiated coverage with a “Buy” rating, setting a target price at $440. This initiation suggests Guggenheim’s analysts see above-average industry performance or potential significant value in the company’s stock, possibly due to strategic initiatives or market positioning that could drive share prices higher.

2. William Blair (January 5, 2026): William Blair also initiated coverage, assigning an “Outperform” rating. Although no specific target price was provided, the “Outperform” status indicates that William Blair forecasts the company to perform better than the average returns of the sector or market index.

3. Wolfe Research (December 10, 2025): Wolfe Research upgraded their rating from “Peer Perform” to “Outperform” with a target price of $480. This upgrade, marked by a substantial target price, reflects a strong conviction in the company’s potential to outperform its peers and suggests significant upside from previous expectations.

4. Morgan Stanley (December 2, 2025): Morgan Stanley initiated coverage with an “Equal-Weight” rating and a target price of $423. This rating implies that the firm views the company’s performance to align closely with the sector average, suggesting a stable outlook but without the aggressive growth potential indicated by other firms.

Overall, the recent ratings indicate a predominantly optimistic view of the company’s market performance, with most analysts suggesting a performance ranging from solid to exceptional relative to peers or sector benchmarks.

The current price of the stock stands at $340.78. Recent analyst ratings suggest a positive outlook, with target prices set significantly higher than the current market price. Guggenheim initiated coverage with a “Buy” rating and a target price of $440, Wolfe Research upgraded their rating to “Outperform” and set a target of $480, and Morgan Stanley rated it as “Equal-Weight” with a target price of $423. These target prices suggest a bullish sentiment among analysts, indicating a potential average upside of approximately 27.5% from the current price.

The absence of specific EPS (Earnings Per Share) and dividend data in the provided information limits a detailed analysis of the company’s earnings trends and dividend policy. However, the optimistic price targets imply that analysts might be expecting strong future earnings, operational growth, or both. Investors should consider these factors along with comprehensive financial analysis and market conditions when evaluating the investment potential of the stock.

Disclaimer: The information provided here is for educational and informational purposes only and should not be interpreted as financial advice, investment recommendations, or trading guidance. Markets involve risk, and past performance is not indicative of future results. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions. By acting, you accept full responsibility for your choices.